Thymogen · 20MG

Thymogen is a synthetic dipeptide bioregulator consisting of the sequence Glu-Trp (EW), one of the earliest and most extensively characterized peptides in the Khavinson cytomedin / cytogen class. The compound was synthesized in the 1970s by Vladislav Khavinson and Vyacheslav Morozov at what became the St. Petersburg Institute of Bioregulation and Gerontology in Russia, originally isolated as the active dipeptide fragment from thymalin (a complex thymic extract). Thymogen functions through tissue-specific gene expression modulation in thymic and immune cell populations and has been investigated extensively in Russian academic literature (Bulletin of Experimental Biology and Medicine; Khavinson, Morozov, Kuznik, and colleagues) for thymic cell biology, T-lymphocyte differentiation pathways, immune gene expression, and age-associated immune cell research endpoints. Russia approved Thymogen as a nasal spray formulation for clinical immunomodulator use; it remains the most clinically-investigated short-peptide Khavinson bioregulator. Like other Khavinson short-peptide bioregulators, Thymogen is studied here primarily as a research tool for tissue-specific peptide pharmacology rather than as a defined receptor agonist.

Benefits (Research Focus)

• Thymic cell biology research — studied for short-peptide bioregulator effects on thymocyte and T-lymphocyte cell populations

• Lymphocyte differentiation pathways — investigated for T-cell maturation marker expression in cell culture research models

• Gene expression modulation — explored for tissue-specific gene expression in thymic and immune cell research

• Khavinson SAR research — examined alongside other Khavinson short-peptide bioregulators (including the closely related Vilon dipeptide) for structure-activity studies

• Age-associated cellular research — researched for thymic cell biology endpoints in aged tissue research models

What Researchers Look At

• T-lymphocyte differentiation markers (CD3, CD4, CD8) in thymocyte cell research

• Gene expression panels in thymic cell research models

• Comparative pharmacology versus Vilon (KE dipeptide) and other Khavinson thymic peptides

• Dipeptide stability, pharmacokinetics, and peptidase resistance research

• Aged-tissue versus young-tissue model responses in comparative thymic cell research

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 20 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Thymogen

• Synonyms: Thymagen; EW dipeptide; Glu-Trp dipeptide; Khavinson thymus/immune peptide bioregulator

• Class: Synthetic dipeptide; Khavinson bioregulator / cytomedin class; thymic immune-targeted

• Sequence: Glu-Trp (EW) — 2 amino acids

• Origin: Khavinson and Morozov, St. Petersburg Institute of Bioregulation and Gerontology (Russia); isolated from thymalin in the 1970s

• Formula / M.W.: C₁₆H₁₉N₃O₅, ~333.34 g/mol (verify against batch COA)

• CAS: 89043-30-1

⚠️ Disclaimer

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Thymogen VPeptide Canada — December 19, 2025